Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized trial of treatments for COVID-19 in hospitalized adults
2020-000936-23Phase 3Completed
- Sponsor
- Inserm
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lopinavir + ritonavir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Inserm. Primary endpoint: Primary: Clinical status at Day 15. Started Mar 2020; status: completed.
02
Drugs
lopinavir + ritonavirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-000936-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000936-23.